Pfizer and Nektar resolve Exubera contract

Share this article:
Pfizer and Nektar resolve Exubera contract
Pfizer and Nektar resolve Exubera contract

Pfizer and Nektar Therapeutics released a joint statement today announcing they have resolved all outstanding contractual issues related to Exubera and Nektar's Phase I next generation inhaled insulin (NGI) product.

Under terms of the agreement, Nektar will receive a one-time payment of $135 million from Pfizer.

In addition, in the event that a new partner is selected, Pfizer has agreed to transfer its remaining rights and all economic benefits for Exubera and NGI. The transfer would include Exubera's New Drug Application and Investigational New Drug Applications and all ex-US regulatory filings and applications, continuation of ongoing Exubera clinical trials and certain supply chain transition activities.

Pfizer CEO Jeffrey Kindler and Nektar CEO Howard Robin issued the following joint statement: “The agreement strengthens our relationship and demonstrates our ability to work together to craft a solution that allows Nektar the ability to pursue additional commercial opportunities for the Exubera and NGI inhaled insulin franchises.”

Some analysts have criticized the way Pfizer exited the Exubera partnership.

During Pfizer's third-quarter earnings call Kindler notified the public of the company's decision to halt marketing of Exubera. Biotech partner Nektar Therapeutics was taken by surprise.

“We first learned…of Pfizer's decision to walk away from Exubera from their press release,” said Howard Robin, president and CEO of Nektar, in a statement.

“We were taken aback by the manner in which [Pfizer] management handled the situation,” Morgan Stanley analyst Jami Rubin wrote in a research note.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...